Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma

NCT00190801 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00190801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00190801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2003
Completion date
September 30, 2005
Enrollment
50
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasms